Citations

Clear

22 citation(s) found for "Menser, T".

Adopting a Standard of Care for Systemic Sclerosis: The Mayo Clinic Experience
Ayala, Ernesto, Iqbal, Madiha , Meier, Tristan, Deng, Yihong, Murthy, Hemant, Foran, James, Ailawadhi, Sikander, Kharfan-Dabaja, Mohamed, Roy, Vivek, Abril, Andy , Menser, Terri , Iqbal, Madiha , Deng, Yihong , Ailawadhi, Sikander , Parrondo, Ricardo D , Kharfan‐Dabaja, Mohamed A. , Roy, Vivek

Mayo Clinic

Arthritis Care & Research | July 31, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1002/acr.80129 | PMID 42533863 Get It

Objective Systemic sclerosis (SSc) is an autoimmune disease marked by immune dysregulation, leading to progressive fibrosis and multiorgan dysfunction. Autologous hematopoietic cell transplantation (autoHCT) has demonstrated superiority over conventional immunosuppression in randomized trials yet remains underused in the United States. We report outcomes following implementation of autoHCT as a standard‐of‐care strategy at our institution. Methods We performed a retrospective analysis of consecutive patients with severe SSc undergoing autoHCT between April 1, 2020, and December 31, 2023. Eligibility required progressive disease despite standard immunosuppressive therapy. Primary endpoints were overall survival (OS) and event free survival (EFS). Secondary endpoints included cumulative incidence of relapse and nonrelapse mortality (NRM), organ‐specific outcomes, and transplant‐related complications. Results Twenty‐five patients underwent autoHCT. Median age was 46 years; 80% were female. At a median follow‐up of 23 (interquartile range 16.4–31.9) months, two‐year OS was 91.67% (95% confidence interval [CI] 81.25–100.0) and EFS was 74.51% (95% CI 58.78–94.45). Two‐year cumulative incidence of relapse was 23.93% (95% CI 4.27 –43.59), and NRM was 8.33% (95% CI 2.97–19.64). Significant improvement in Modified Rodnan Skin Score was observed at day +90 and +180 ( P < 0.05), whereas pulmonary function stabilized. Infectious complications occurred in 56% of patients, primarily viral reactivations. Conclusion Implementation of autoHCT for severe SSc in a multidisciplinary care model was associated with favorable survival and meaningful improvement in skin disease, with acceptable toxicity. Earlier referral and optimization of conditioning strategies may further reduce relapse and treatment‐related morbidity.
Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma
Abdallah, Nadine , Marar, Rosalyn, Yee, Claire , Bodily, Anna, Truman, Mia, Wildes, Tanya, Weivoda, Megan , Aug, Sarah, Smith, Byron, Kapoor, Prashant , Hayman, Suzanne R. , Dingli, David, Gonsalves, Wilson I, Zanwar, Saurabh , Kourelis, Taxiarchis , Warsame, Rahma , Lin, Yi, Rajkumar, S Vincent, Kumar, Shaji , Yee, Claire , Menser, Terri , Weivoda, Megan , Buadi, Francis K , Dispenzieri, Angela , Cook, Joselle M , Zanwar, Saurabh S , Binder, Moritz , Kourelis, Taxiarchis , Gertz, Morie A , Warsame, Rahma , Dueck, A. C. , Kumar, Shaji K , Wildes, Tanya M. , Buadi, Francis K. , Dispenzieri, Angela , Dingli, David , Gonsalves, Wilson I. , Cook, Joselle , Binder, Moritz , Gertz, Morie A. , Rajkumar, S. Vincent , Dueck, Amylou C.

Mayo Clinic

Blood Advances | July 28, 2026 | Volume: 10 | Issue: 20 | Pages: 6957-6967

10.1182/bloodadvances.2026020579 | PMID 42508993 Get It

Abstract Frailty influences treatment outcomes in older patients with multiple myeloma (MM), yet existing frailty tools capture limited geriatric domains and are incompletely studied in the context of contemporary therapies. We prospectively evaluated patient-reported comprehensive geriatric assessment (CGA) domains and their associations with treatment toxicity and patient-reported outcomes (PRO) in older adults with MM. Patients aged ≥60 years with newly diagnosed or relapsed/refractory MM initiating a new therapy completed electronic CGA and PRO questionnaires at baseline and 4 months. Outcomes included clinician- and patient-reported treatment toxicity, treatment adaptations, health care use, and health-related quality of life (HRQOL). A cumulative deficit frailty index (FI) was derived from CGA and HRQOL domains. Among 90 patients (mean age, 72 years), geriatric impairments were common, particularly physical function domains. High-grade nonhematologic toxicities were significantly associated with older age, comorbidities, patient-reported functional limitations, and anxiety. Toxicity rates on the PRO version of the Common Terminology Criteria for Adverse Events (CTCAE) were higher than on CTCAE, highlighting a discordance between physician- and patient-reported treatment toxicity. Frailty was present in 22% and associated with worse baseline HRQOL and increased high-grade nonhematologic toxicity but not treatment adaptations or health care use. Average CGA and HRQOL scores remained stable over 4 months, although individual trajectories varied. Patient-reported geriatric impairments are prevalent in older adults with MM and strongly associated with nonhematologic toxicities even in the contemporary treatment era. Physician-reported CTCAE may not fully reflect patients' symptom burden. Heterogeneity in individual geriatric trajectories during treatment emphasize the need for longitudinal assessment. This study was registered at www.clinicaltrials.gov as NCT05918185.
C54-15 Association of Early Norepinephrine Administration and Cumulative Dose With Oxygenation and Clinical Outcomes in Patients With Septic Shock
Fabrega, A A, Guardia, M E Berguido de la, Menser, T, Kashani, K, Franco, P Moreno, Reddy, S, Kashani, Kianoush , Franco, P. Moreno

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6234 Get It

Abstract Rationale Septic shock patients require vasopressors to maintain adequate mean arterial pressure (MAP). The 2021 Surviving Sepsis Campaign Guideline recommends norepinephrine (NE) as first line, followed by vasopressin (VP). Early NE initiation is associated with faster achievement of MAP goals, lower fluid requirements, increased PaO2/FiO2 ratio, more mechanical-free ventilation days, and lower mortality. However, higher NE dosages can cause excessive vasoconstriction, impaired perfusion, lower Pa/Fi ratios, and increase in-hospital mortality. We tested the association between timing and cumulative dose of the NE with PaO2/FiO2 ratio, duration of invasive mechanical ventilation (IMV) and hospital length of stay (LOS). Methods We conducted a retrospective cohort analysis of adult septic shock patients treated with NE at Mayo Clinic Rochester Medical ICU between January 3, 2006, and April 17, 2018. Patients receiving other initial vasopressors were excluded. We developed linear regression models to assess how NE initiation time, defined as hours from sepsis identification, and cumulative dose, defined as total NE administered during ICU stay, affected median PaO2/FiO2 ratio, duration of IMV, and hospital LOS. We assessed for associations using: 1) an unadjusted model; 2) an adjusted model for baseline demographics and comorbidities (age, sex, weight, and Charlson Comorbidity Index); 3) an adjusted model for illness severity on day 1, using APACHE III and SOFA scores. Results Of 1,082 patients, 70% (n = 759) started NE as initial vasopressor. Timing of NE initiation was independently linked to shorter IMV and hospital LOS, but not to PaO2/FiO2 ratio. Across all models, earlier NE use significantly reduced IMV duration (β over 1.3992 ± 0.11 and p &lt; 0.0001) and hospital LOS (average β 0.067 ± 0.01 and p &lt; 0.0001). In contrast, a higher cumulative NE dose during the ICU stay was associated with a lower median PaO2/FiO2 ratio (β: -0.0053 ± 0.002, p = 0.0061), and remained significant in the adjusted models (β -0.0065 ± 0.002, p = 0.0013; and β -0.005 ± 0.002, p = 0.0132). Additionally, higher NE doses were significantly associated with longer IMV duration and hospital LOS in all models with p &lt; 0.0001. Conclusion Although earlier initiation of vasopressor support with NE is associated with shorter durations of IMV and hospital LOS, higher cumulative doses are linked to the opposite effect. Increased NE doses were associated with lower PaO2/FiO2 ratios, delayed extubation and prolonged hospitalization. These findings highlight the importance of early NE administration and careful dose titration to optimize patient recovery. This abstract is funded by: None
C66-19 Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure Ratio in Prognosis of Portopulmonary Hypertension Patients Undergoing Liver Transplant
Ghosh, S, Saunders, H, Assis, M, Corro, R, Frias, J E Sinclair De, Khanijo, A, Milian, R Diaz, Menser, T, Reddy, P, O’Sullivan, S, Patel, P, Torp, K, Burger, C D, Franco, P Moreno, Saunders, Hollie , Corro, Rosa, FRÍAS, JORGE SINCLAIR DE , Milian, Ricardo Diaz , Menser, T, O'Sullivan, S, Torp, Klaus D. , Franco, P. Moreno

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.5865 Get It

Abstract Rationale Transthoracic echocardiography (TTE) is a very useful measure of cardiac function in patients with pulmonary hypertension (PH), along with right heart catheterization, which is considered to be the gold standard of measurement. It is non-invasive, quick and a good screening tool to assess the function of a failing right ventricle against elevated pulmonary pressures. Portopulmonary hypertension (POPH) is defined as PH associated with portal hypertension. The Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Artery Pressure (TAPSE/SPAP) ratio has been found to be an effective prognosticator in different subtypes of PH. This study focuses on the role of TAPSE/SPAP ratio in prognosis of patients with POPH undergoing liver transplantation. Methods This was a single-center retrospective study of POPH patients undergoing liver transplantation at Mayo Clinic Florida from June 2003 to December 2023. It included patients with POPH with a mean pulmonary pressure &gt;20 mm Hg undergoing liver transplantation. Patients with incomplete TTE data, coexisting renal failure on dialysis and requiring liver retransplant were excluded. This study included 27 patients. The last TTE report before liver transplantation was used for data analysis. The TAPSE/SPAP ratio was investigated as predictor of all-cause mortality following liver transplant using Cox regression and area under ROC curve. (Brackets contain 95% C.I.) Time to death after liver transplantation was considered. Patients were followed till August 1, 2024. (The correlation of this ratio-TAPSE/SPAP with some catheterization measured pulmonary pressures and indices have been included in Table 1.) Results Among 27 patients, 13 were female, 14 male. The most common causes of liver failure in these patients were non alcoholic fatty liver disease (NASH) and alcoholic liver disease. Rarely, some etiologies like sarcoidosis, autoimmune hepatitis, primary sclerosing cholangitis and hepatitis B/C were present. There were 7 deaths among total of 27 patients. The hazard ratio (HR) of TAPSE/SPAP for overall mortality by Cox regression was 0.01 (0.00-0.58), p = 0.03. The area under ROC curve was 0.76 (0.55-0.96), p = 0.01 [Also for TAPSE alone, the area under ROC curve was 0.74 (0.51-0.97), p = 0.05] Conclusion This study infers that TAPSE/SPAP ratio seems to be a good predictor of survival in POPH patients undergoing liver transplant, with a higher ratio associated with decreased all-cause mortality. It suggests that TAPSE alone might also be a good predictor with higher TAPSE associated with decreased mortality. This abstract is funded by: None
B54-07 Hypophosphatemia Is Independently Associated With Prolonged Mechanical Ventilation in Patients With Septic Shock
Guardia, M E Berguido de la, Fabrega, A A, Menser, T, Kashani, K, Franco, P Moreno, Reddy, S, Kashani, Kianoush , Franco, P. Moreno

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.4676 Get It

Abstract Rationale Hypophosphatemia affects about one-third of intensive care unit (ICU) patients and is linked to longer hospital stays, illness severity and poor outcomes, yet guidelines for monitoring and correction remain unclear. Studies show a strong association between hypophosphatemia and both prolonged invasive mechanical ventilation (IMV) and weaning failure in patients with respiratory failure, due to reduced adenosine triphosphate generation and weakened respiratory muscle performance. Although phosphate abnormalities correlate with higher mortality in sepsis and septic shock, their impact on IMV duration in this population remains unclear. Therefore, we aimed to evaluate the independent association between hypophosphatemia during ICU stay and the duration of IMV in patients with septic shock. Methods We studied adult patients with septic shock admitted to the medical ICU at Mayo Clinic, Rochester, between March 1, 2006, and April 17, 2018. A retrospective analysis was conducted to examine the association between hypophosphatemia—defined as any serum phosphate level &lt; 2.5 mg/dL during the ICU stay—and the duration of IMV in hours. The following linear regression models were used: 1, unadjusted; 2, adjusted for baseline demographics (age, sex, weight); 3, adjusted for baseline respiratory comorbidities and Charlson Comorbidity Index (CCI); and 4, adjusted for illness severity (using APACHE III and SOFA scores) and oxygenation (minimum PaO2/FiO2 score during ICU stay). For each model, the β-coefficient was reported, which represents additional hours of IMV associated with hypophosphatemia, along with 95% confidence intervals and p-values. Results The study included 1082 patients, among them 653 (60.4%) required IMV. 53.6% (n = 350) developed hypophosphatemia during their ICU stay. The mean duration of IMV was significantly longer in patients with hypophosphatemia compared with those without (184 ± 218 h vs 100 ± 126 h; p &lt; 0.001; 95% CI 56-112). This association persisted across all multivariable linear regression models. After adjustment for baseline demographics, hypophosphatemia remained significantly associated with longer IMV duration (β = 79.8 h; 95% CI 51.8-107.8; p &lt; 0.001). Further adjustment for respiratory comorbidities and CCI yielded similar results (β = 81.8 h; 95% CI 54.2-109.4; p &lt; 0.001). After controlling for illness severity and oxygenation status, hypophosphatemia remained independently associated with prolonged IMV duration (β = 69.2 h; 95% CI 39.9-98.4; p &lt; 0.001). Conclusion Hypophosphatemia was independently associated with longer duration of IMV in patients with septic shock, which prolongs ICU level care and delays rehabilitation. This highlights the need for updates on guidelines for maintaining optimal serum phosphate levels in patients who are mechanically ventilated. This abstract is funded by: None
Self-reported geriatric impairments and treatment toxicity in older patients with multiple myeloma - a single center prospective study
Marar, Rosalyn, Bodily, Anna, Weivoda, Megan , Aug, Sarah, Kapoor, Prashant , Hayman, Suzanne R. , Cook, Joselle , Zanwar, Saurabh , Kourelis, Taxiarchis , Warsame, Rahma , Lin, Yi, Kumar, Shaji , Abdallah, Nadine , Yee, Claire , Wildes, Tanya M. , Menser, Terri , Buadi, Francis K. , Gonsalves, Wilson I. , Dispenzieri, Angela , Muchtar, Eli , Dingli, David , Cook, Joselle , Binder, Moritz , Gertz, Morie A. , Rajkumar, S. Vincent , Dueck, Amylou C.

Mayo Clinic

Blood | December 5, 2025 | Volume: 146 | Issue: Supplement 1 | Pages: 715-715

10.1182/blood-2025-715 Get It

Abstract Introduction: Multiple myeloma (MM) predominantly affects older adults who vary widely in physiological status and treatment outcomes. Comprehensive Geriatric Assessment (CGA) is considered the gold standard for frailty assessment in older cancer patients (pts), but clinical useis limited. Current frailty tools for MM include only select GCA domains, rely on trial datasets, and do not incorporate pt-reported outcomes (PROs). Since their development, treatment strategies have evolved with the use of anti-CD38 MAbs and quadruplets in older pts. The impact of geriatric impairments on treatment tolerance in the era of modern therapy remains unclear and changes in geriatric domains during treatment are not well characterized. Aim: This prospective study evaluates the association between pt-reported CGA and treatment outcomes in older MM pts.Methods: We included MM pts ≥60 years initiating a new treatment at Mayo Clinic from March 2023-June 2024. Pts completed the CARG GCA (Hurria et al 2005) electronically prior to and after 4 treatment cycles. We collected data on toxicity using CTCAE and PRO-CTCAE and quality of life using the PROMIS10-GH SF.Results: Ninety pts were enrolled. Median age was 72 (range: 63-86), 42% female, and &gt;90% non-Hispanic white. Over half (59%) were newly diagnosed with 41% and 56% receiving quadruplets and triplets, respectively. Among newly diagnosed pts, 34% had early stem cell transplant. Baseline median self- and physician- reported KPS were 80% and 90%, respectively, with high correlation (r=0.657). The median number of meds per pt was 9 (range:0-30), 39% had ≥3 comorbidities, 21% reported ≥1 fall in the past 6 months, and 40% reported ≥1 IADL limitation. On the Hospital Anxiety and Depression Scale, 3% and 7% had anxiety and depression, respectively. On the Blessed Orientation-Memory-Concentration test, 19% had mild cognitive impairment, and 1% had severe cognitive impairment. While only 19% had grade (G) ≥3 non-hematologic toxicity by CTCAE, 71% had ≥1 treatment delay, dose reduction, or discontinuation, and 39% had ≥1 ED visit or unplanned hospitalization within the first 4 cycles. This suggests physician grading of non-hem toxicities may inadequately capture toxicity burden from MM therapy. Notably, the rate of G≥3 toxicity by PRO-CTCAE was 49%, highlighting the discrepancy between physician- and pt-reported symptom burden. CGA domains significantly associated with G≥3 non-hem toxicity were: age (74 v 71.5, p=0.032), ≥3 comorbidities (65% v 33%, p=0.015), anxiety (18% v 0%, p=0.006), ≥1 IADL limitation (65% v 33%, p=0.018), physician KPS ≤80 (53% v 27%, p=0.042), limitations in vigorous activities (100% v 78%, p=0.023) and limitations in climbing several flights of stairs (88% v 56%, p&lt;0.001). Predictors of PRO-CTCAE G≥3 toxicity were ≥1 falls (30% v 11%, p=0.030), ≥3 comorbidities (52% v 26%, p=0.011), polypharmacy (≥9 meds) (67% v 43%, p=0.023), and physician KPS ≤80 (43% v 22%, p=0.030). CGA domains associated with ≥1 treatment adjustments were polypharmacy (62% v 33%, p=0.017) and unintentional weight loss (35% v 12%, p=0.028). Polypharmacy was the only domain associated with healthcare utilization (68% v 45%, p = 0.040), which may reflect underlying multimorbidity and greater pain burden. On multivariable logistic regression, any level of limitation in climbing several flights of stairs (OR: 6.0, 95% CI 1.2-30.3; p= 0.030) and older age (OR: 1.1, 95% CI 1.0-1.1; p=0.032) were independently associated with G≥3 non-hem toxicity, reflecting impaired functional status and reduced physiologic reserve, while ≥3 comorbidities only trended toward significance (OR:1.9, 95% CI 1.1-3.9, p=0.051).Compared to baseline, there were no significant changes in CGA domains or PROMIS10 scores after 4 cycles. While there was no significant difference in the proportion of pts reporting limitations in IADLs or physical function, we observed heterogeneity among individual pts, with changes in all 3 directions (improvement, stability, and decline). Conclusions: Geriatric impairments are prevalent in older pts with MM; pt-reported impairments are significantly associated with G≥3 non-hem toxicities, need for treatment modifications, and increased healthcare utilization, even in the era of novel therapies. Physical functional trajectories during treatment are variable among individual pts, underscoring the need for personalized treatment strategies and reassessment of geriatric domains throughout treatment.
Abstract 4368921: Artificial Intelligence Prediction of Atrial Fibrillation Using Pre-Cannulation Electrocardiograms in Patients Undergoing Veno-Venous Extracorporeal Membrane Oxygenation
Corro, Rosa, Khanijo, Aditya , Ghosh, Saptarshi, Chaudhary, Sanjay , Goswami, Rohan , Desai, Aarti , Vergara‐Sanchez, Carlos , Olivero, Lorenzo , Menser, Terri , Guru, Pramod , Goswami, Rohan , Franco, Pablo Moreno

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4368921 Get It

Backround: Atrial fibrillation (AF) is a common complication following veno-venous extracorporeal membrane oxygenation (VV-ECMO), leading to further complications from anticoagulation or stroke. The Artificial Intelligence AF Prediction Dashboard developed at Mayo Clinic generates two predictive outputs: (1) a continuous probability score and (2) a binary threshold-based signal to predict the likelihood of AF at an individual level after 12-lead electrocardiogram (ECG) is obtained. Using both continuous risk (%) and binary (yes/no) likelihood, we present a novel method to understand AF risk after VV-ECMO cannulation based on pre-ECMO 12-lead ECG. Methods: We reviewed a total of 147 patients on ECMO between 2018 and 2024, from which 85 VV-ECMO patients with complete data were included. AI Dashboard outputs were quantified as binary (1/0) or percent likelihood for AF. R was utilized for statistical analysis. Results: 85 patients met our inclusion criteria from which AF after cannulation occurred in 31 (36%). 17 patients had a history of AF prior to VV-ECMO initiation. The mean age of our cohort was 49 years with a mean BMI of 29.3. Baseline AI Dashboard continuous assessment identified 39 patients (46%) compared to the binary assessment identifying 31 patients (36%). Logistic regression in the binary assessment demonstrated an odds ratio of 1.08 (95% CI 1.04 – 1.12) with a p value of <0.001. The binary AF Prediction yielded a 58% sensitivity, 76% specificity, 58% PPV, and 76% NPV, with an accuracy of 67%. The continuous AF Probability score achieved 72% balanced accuracy with sensitivity 74%, specificity 70%, PPV 59% and NPV 83%, indicating fair overall performance and suggesting good utility for ruling out AF in low-risk patients. Although both outputs provided moderate predictive accuracy, the continuous score reported before ECMO cannulation demonstrated stronger overall performance with fewer false negatives and higher rule-out value. Conclusions: We demonstrate the novel use of an AI predictive model in the VV-ECMO population for the prediction of AF risk with both continuous and binary risk cutoffs from baseline ECG. This data highlights the need for further development in ECMO-specific AI models to help mitigate risk after the onset of atrial arrhythmias. As AI-driven tools become increasingly integrated into care, their performance must be continuously validated and recalibrated for specific populations to ensure their safe and effective use.
Abstract 4367974: Troponin Elevation Identifies High-Risk Septic ICU Patients Without Prior Cardiac Disease
Khanijo, Aditya , Corro, Rosa, Vergara, Carlos , Galeano, Santiago, Forrest, M J, Chapman, Anthony, Eklund, Selma, Fernández, Carlos , Ganupa, Sneha, Goswami, Rohan , Chaliki, Hari P. , Ghosh, Saptarshi, Desai, Aarti , Forrest, Marion, Chapman, Anthony, Eklund, Selma, Fernandez, Chrystinne, Tohyama, Takeshi , Menser, Terri , Goswami, Rohan , Bhattacharyya, Anirban , Franco, Pablo Moreno

Mayo Clinic

Circulation | November 3, 2025 | Volume: 152 | Issue: Suppl_3 | Pages: No page available

10.1161/circ.152.suppl_3.4367974 Get It

Problem Statement: The prognostic value of troponin elevation in septic ICU patients without known history of cardiac disease remains unclear, particularly after accounting for overall illness severity. Background: Minor troponin rises are frequent during sepsis, yet clinicians still lack a clear cut-point that signals danger once cardiac disease is ruled out. We asked whether a modest increase in troponin-T predicts in-hospital death beyond global illness severity. Methods: We studied 1 221 adult first ICU stays labelled “sepsis” in the eICU Collaborative Research Database and removed any case with a cardiac admission diagnosis. Implausible or missing laboratory values were imputed by multiple imputation. Hospital mortality was modelled with logistic regression that included troponin (a continuous and a binary model with threshold > 0.04 ng/mL) together with age, sex, lactate, albumin, BUN, creatinine, intubation status, vasopressor use, dialysis requirement and APACHE-IV predicted mortality. A natural-spline model explored non-linear behavior. Findings were checked in a 1:1 propensity-matched cohort. Results: Overall mortality was 11.7%. Troponin exceeded 0.04 ng/mL in 38% of patients. After adjustment for APACHE-IV probability and other covariates, a troponin level > 0.04 ng/mL was associated with almost twice the odds of death (OR ≈ 1.9), whereas the continuous model suggested only a modest trend (OR ≈ 1.1 per ng/mL). The spline curve rose steeply between 0 and 0.10 ng/mL and flattened thereafter, pinpointing an inflection near 0.05 ng/mL. Matching on all measured confounders confirmed that high-troponin patients had about three-fold greater mortality (OR ≈ 2.8, 1.55-5.05; p<0.001), highlighting that even modest troponin elevation is an independent risk marker for death in septic ICU patients. A bedside heat-map combining troponin, albumin and need for intubation illustrated a simple gradient: risk climbs from 2 % in low-troponin, well-albuminised, non-intubated patients to nearly 7 % when troponin exceeds 0.10 ng/mL in intubated, hypo-albuminemic patients. Conclusions: Even modest troponin elevations (> 0.04 ng/mL) independently predict mortality in sepsis after rigorous adjustment and matching on APACHE-IV physiology, lactate, and organ-support variables. This biologic threshold supports incorporating troponin into bedside triage and future septic cardiomyopathy trials.